# Sirolimus for Nosebleeds in HHT

> **NCT05269849** · PHASE2 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 10 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Nosebleeds
- Epistaxis

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT05269849
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-16
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269849, "Sirolimus for Nosebleeds in HHT". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05269849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*